Exposure levels and target attainment of piperacillin/tazobactam in adult patients admitted to the intensive care unit: a prospective observational study
Authors' conclusion
In this prospective observational study of adult ICU patients receiving intravenous PTZ, a large proportion had subtherapeutic concentrations of piperacillin. This was most notable in patients with normal to augmented renal clearance.
Study context
- Population
- Adult intensive care unit (ICU) patients (≥18 yr) receiving intravenous piperacillin/tazobactam (PTZ), Level I trauma centre, Montreal, Canada, January 2021–June 2022202 blood samples analysed
- Participants
- 43 patients
- Outcome
- Pharmacodynamic target attainment: middle- and end-of-interval total piperacillin concentration above MIC of 16 mg·L-1
- Follow-up
- Study days 1, 4 and 7 of therapy
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Patients not reaching efficacy target (trough concentration of 16 mg·L-1)
37%
Median [IQR] piperacillin concentration at peak (mg·L-1)
109.4
74.0–152.3
Median [IQR] piperacillin concentration at middle of interval (mg·L-1)
59.3
21.1–74.4
Median [IQR] piperacillin concentration at end of interval (mg·L-1)
25.3
6.8–44.6
Observational data: associations, not effects.
Further findings
Most prevalent dose: 3/0.375 g every six hours, 30-min infusion
- Doses administered at 3/0.375 g every six hours
- 50/73 (68%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →